Abstract
Mutations in nuclear genes involved in the maintenance of mitochondrial DNA (mtDNA) are associated with an extensive spectrum of clinical phenotypes, manifesting as either mtDNA depletion syndromes or multiple mtDNA deletion disorders.1
Mutations in nuclear genes involved in the maintenance of mitochondrial DNA (mtDNA) are associated with an extensive spectrum of clinical phenotypes, manifesting as either mtDNA depletion syndromes or multiple mtDNA deletion disorders.1
Mutations in thymidine kinase 2 (TK2; GenBank accession number NM_004614.4) have been reported to cause an early fatal myopathic mtDNA depletion syndrome,2 culminating in respiratory failure with or without encephalopathy,3 adult-onset indolent myopathy,4 or progressive external ophthalmoplegia (PEO) associated with multiple mtDNA deletions.1 We describe a 74-year-old woman who presented with ptosis, a limb-girdle muscular dystrophy–like phenotype, and progressive respiratory failure due to recessive TK2 mutations and multiple mtDNA deletions in muscle.
Methods.
Case report.
A 74-year-old woman with sensorineural hearing loss (SNHL) presented with progressive muscle weakness and rapidly progressive respiratory failure, decompensated following iatrogenic oxygen administration. She improved clinically with withdrawal of high-dose oxygen therapy and was subsequently discharged for domiciliary ventilation. She had presented 2 years previously for surgical correction of ptosis but had no other medical history of note. Her parents lived to old age and she has an 82-year-old clinically unaffected brother.
On examination, she had mild ptosis, subtle PEO, facial weakness, marked wasting of proximal musculature, including sternocleidomastoids, and scapular winging, and neck flexion and extension were weak (figure, A). Hip flexion (Medical Research Council [MRC] grade 2) and dorsiflexion were weak (MRC grade 4) with relative preservation of hip extensors, knee extension, and plantar flexion. Tendon reflexes were intact and she was not ataxic. Standard histopathologic analysis of a muscle biopsy was performed. DNA was extracted from muscle homogenate and individual muscle fibers and subjected to quantitative and qualitative mtDNA analysis. Candidate mtDNA maintenance disorder genes (POLG, POLG2, SLC25A4, PEO1, and RRM2B) were excluded, prompting screening of the entire coding region of the TK2 gene. Sequence variants were cross-referenced against dbSNP (build 135) and variants of unknown pathologic significance investigated using in silico methodologies. Total RNA was derived from patient fibroblasts and reverse transcribed to cDNA using a TK2-specific primer (details available on request). Allele-specific primers incorporating and exploiting 2 in cis single nucleotide polymorphisms prompted allele dropout to establish phase. To investigate the pathogenicity of the novel p.Lys194Asn variant, site-directed mutagenesis was employed to engineer the mutation in the human TK2 protein, and express this and wild-type human TK2 in Escherichia coli. Purification of the protein and determination of enzyme activity was performed as previously described5 (see appendix e-1 on the Neurology® Web site at www.neurology.org).
Results.
Muscle biopsy analysis revealed evidence of fiber diameter variation and internal nuclei and fat replacement, in addition to 20% COX-deficient fibers and subsarcolemmal mitochondrial accumulation (figure, B). Long-range PCR revealed multiple mtDNA deletions, while mtDNA copy number assessment showed increased (185% of control values) mtDNA levels. Individual COX-deficient and COX-positive muscle fibers confirmed comparable mtDNA copy number (figure, D) but clonally expanded MTND4 gene deletions in the majority of COX-deficient muscle fibers (figure, E), diagnostic of a multiple mtDNA deletion disorder.6
Sequencing of the TK2 gene revealed 2 novel heterozygous variants: a nonsense mutation (c.103C>T, predicting p.Gln35*) and a missense variant (c.582 G>T, predicting p.Lys194Asn). Analysis of fibroblast-derived patient cDNA confirmed recessive inheritance of the 2 novel TK2 variants (figure, C) while we were not able to detect either of these changes in the patient’s clinically unaffected brother.
Direct measurement of recombinant p.Lys194Asn TK2 activity confirmed a marked reduction in the Vmax relative to the wild-type sample while the Km of the p.Lys194Asn enzyme did not differ from that of the wild-type enzyme (figure, F).
Discussion.
We report a very late presentation of respiratory failure in a 74-year-old woman with TK2 gene mutations associated with late-onset myopathy and minimal PEO. To date, 54 patients have been described in the literature, presenting with either mtDNA depletion or multiple mtDNA deletion disorders due to recessive TK2 mutations (table e-1). SNHL has been described and facial weakness,1,4,7 ptosis, and eye movement abnormalities are not infrequent.1,7 Overt respiratory muscle weakness or failure is almost universally reported.
The p.Gln35* nonsense mutation is assumed to be subject to nonsense-mediated decay of the corresponding mRNA. Pathogenicity of the p.Lys194Asn mutation is supported by functional evidence from the recombinant mutant enzyme that shows the same affinity for its substrate but a clear reduction in Vmax, confirming a decreased efficacy of the mutant TK2 protein. The observed elevation in muscle mtDNA copy number suggests a compensatory mechanism that could account for the late onset of our patient's clinical symptoms, particularly given 1 mutation represents a null allele.
The demonstration of recessive TK2 mutations highlights that mtDNA maintenance disorders should be considered in cases of late-onset myopathy where respiratory failure is prominent, irrespective of age.
Supplementary Material
Footnotes
Supplemental data at www.neurology.org
Author contributions: C.L.A.: analysis and interpretation of data, acquisition of data, statistical analysis. A.M.S.: analysis and interpretation of data, critical revision of the manuscript for important intellectual content. P.R.: analysis and interpretation of data. N.S.: analysis and interpretation of data. K.J.K.: analysis and interpretation of data. E.L.B.: analysis and interpretation of data. L.H.: analysis and interpretation of data. K.C.: analysis and interpretation of data. M.R.: study concept and design. A.V.: analysis and interpretation of data. J.N.: analysis and interpretation of data. R.H.: study concept and design, critical revision of the manuscript for important intellectual content. D.M.T.: study concept and design, critical revision of the manuscript for important intellectual content, obtaining funding. A.K.: analysis and interpretation of data. G.S.G.: study concept and design, critical revision of the manuscript for important intellectual content, study supervision and coordination. R.W.T.: study concept and design, critical revision of the manuscript for important intellectual content, study supervision and coordination, obtaining funding.
Study funding: The mitochondrial diagnostic laboratory in Newcastle-upon-Tyne is funded by the UK NHS Specialised Services to provide the “Rare Mitochondrial Disease of Adults and Children” service (http://www.newcastle-mitochondria.com/service/clinical/). G. Gorman is supported by the UK NIHR Biomedical Research Centre for Ageing and Age-related Disease award to the Newcastle-upon-Tyne Foundation Hospitals NHS Trust. R. Taylor is supported by a Wellcome Trust Strategic Award (096919Z/11/Z) and the MRC Centre for Translational Research in Neuromuscular Disease Mitochondrial Disease Patient Cohort (UK) (G0800674).
Disclosure: C. Alston, A. Schaefer, P. Raman, N. Solari, K. Krishnan, E. Blakely, L. He, K. Craig, M. Roberts, A. Vyas, and J. Nixon report no disclosures. R. Horvath is supported by the Medical Research Council (UK) (G1000848). D. Turnbull is supported by a Wellcome Trust Strategic Award (096919Z/11/Z), the MRC Centre for Neuromuscular Diseases (G0601943), and the MRC Centre for Translational Research in Neuromuscular Disease Mitochondrial Disease Patient Cohort (UK) (G0800674). A. Karlsson is supported by the Swedish Research Council (K2011-66X-12162-15-3). Go to Neurology.org for full disclosures.
References
- 1.Tyynismaa H, Sun R, Ahola-Erkkilä S, et al. Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. Hum Mol Genet 2012;21:66–75 [DOI] [PubMed] [Google Scholar]
- 2.Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 2001;29:342–344 [DOI] [PubMed] [Google Scholar]
- 3.Blakely E, He L, Gardner JL, et al. Novel mutations in the TK2 gene associated with fatal mitochondrial DNA depletion myopathy. Neuromuscul Disord 2008;18:557–560 [DOI] [PubMed] [Google Scholar]
- 4.Paradas C, PG Ríos, Rivas E, Carbonell P, Hirano M, DiMauro S. TK2 mutation presenting as indolent myopathy. Neurology 2013;80:504–506 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lesko N, Naess K, Wibom R, et al. Two novel mutations in thymidine kinase-2 cause early onset fatal encephalomyopathy and severe mtDNA depletion. Neuromuscul Disord 2010;20:198–203 [DOI] [PubMed] [Google Scholar]
- 6.He L, Chinnery PF, Durham SE, et al. Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res 2002;30:e68. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Béhin A, Jardel C, Claeys KG, et al. Adult cases of mitochondrial DNA depletion due to TK2 defect: an expanding spectrum. Neurology 2012;78:644–648 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.